Niagen Bioscience, Inc. NAGE
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -125.62% | -73.32% | 24.79% | -42.44% | 143.77% |
| Total Depreciation and Amortization | 31.75% | 32.39% | 26.09% | 2.79% | -1.91% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -5.63% | 13.90% | -1,147.60% | 96.26% | 135.16% |
| Change in Net Operating Assets | 155.43% | 89.03% | -290.94% | -171.79% | -697.22% |
| Cash from Operations | -28.90% | 121.76% | -115.15% | -92.09% | 5.64% |
| Capital Expenditure | -116.67% | 34.07% | -90.63% | -46.38% | 41.46% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -116.67% | 31.85% | 16,490.63% | -46.38% | -14.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 0.00% | 0.00% |
| Issuance of Common Stock | 28.95% | -92.59% | -96.44% | -93.99% | -85.43% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -683.33% | -34.15% | -- |
| Cash from Financing | 32.43% | -166.50% | -173.75% | -102.13% | -85.76% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -27.44% | -96.07% | -83.93% | -95.94% | -15.44% |